The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.
RSS Feed for InvestorBrandNetwork (IBN)April 20, 2026 — Backers of a proposed medical marijuana measure in Idaho say they have surpassed 100,000 collected signatures and are now racing to meet an April 30 deadline that would place the issue before voters in November. Advocates for marijuana policy reform, as well as industry actors like TerrAscend Corp.
April 20, 2026 — Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
April 20, 2026 — Massimo Group (NASDAQ: MAMO) announced the appointment of Quenton Petersen as Chief Executive Officer, effective April 14, 2026, with David Shan transitioning to Executive Chairman while remaining actively involved in the Company’s strategic direction. Petersen, a nine-year veteran of the company, emphasized continued growth across utility vehicles and electric mobility, alongside a disciplined evaluation of opportunities to integrate advanced technologies such as AI-enabled features and expand into applications including facility operations and smart mobility.
April 20, 2026 — Genius Group (NYSE: GNS) announced the closing of its previously disclosed registered direct offering, raising gross proceeds of approximately $8. 0 million through the sale of 21,621,621 ordinary shares (or pre-funded warrants in lieu thereof).
April 20, 2026 — By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J.
April 20, 2026 — Channelchek, a Noble Financial Group platform, highlights a changing investment landscape in 2025, where capital is increasingly rotating toward differentiated growth opportunities beyond crowded sectors. Within this environment, Enhanced Group Inc.
April 20, 2026 — Wearable Devices (NASDAQ: WLDS) announced a planned cooperation and partnership with Meta-Bounds Inc. to integrate its Mudra neural wristband technology with augmented reality hardware, aiming to enable seamless, touchless spatial interaction.
April 20, 2026 — Oragenics (NYSE American: OGEN) announced that two patients have been enrolled and eight doses administered in its ongoing Phase IIa clinical trial evaluating ONP-002, its lead candidate for the treatment of mild traumatic brain injury (mTBI), or concussion. The trial is underway at Mackay Base Hospital in Queensland, Australia, with additional sites nearing activation, as the company advances a first-in-class intranasal neurosteroid designed to target the underlying biological effects of brain injury, addressing a significant unmet need in a market with no FDA-approved pharmacological treatments.
April 20, 2026 — OptimumBank Holdings (NYSE American: OPHC) announced that Brean Capital, LLC has initiated equity research coverage of the company, with Director of Research Christopher Marinac assigning a Buy rating and an $8 price target. The report, distributed to Brean’s institutional client base, underscores growing recognition of the company’s business model, operating performance and long-term growth strategy, according to Chairman Moishe Gubin, who highlighted the initiation as a key step in expanding investor awareness.
April 20, 2026 — This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.
April 20, 2026 — Beeline is integrating its mortgage and title platform into a broader AI-driven real estate ecosystem, with embedded finance emerging as an important distribution model in residential real estate. The SRG partnership targets up to 2,000 home financings in a defined, multi-year development pipeline.
April 20, 2026 — Oncotelic Therapeutics (OTCQB: OTLC) is featured in recent BioMedWire editorial coverage highlighting a fundamental shift in biotechnology, where scientific progress is increasingly recognized as measurable financial value rather than purely as research expenditure. As clinical-stage assets advance toward commercialization, fair-value accounting frameworks under U.
April 20, 2026 — This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) welcomed a White House Executive Order aimed at accelerating research, regulatory pathways and patient access to psychedelic treatments, citing its potential to prioritize FDA review, expand access and strengthen interagency coordination.
April 20, 2026 — Aditxt (NASDAQ: ADTX) announced its precision oncology subsidiary, Ignite Proteomics, was featured in a peer-reviewed study published in npj Precision Oncology, a Nature journal, evaluating treatment outcomes in metastatic breast cancer patients receiving trastuzumab deruxtecan. The study found that quantitative HER2-related assays, including Ignite’s Reverse Phase Protein Array platform, provided more predictive insight into patient outcomes than traditional immunohistochemistry methods in certain sub-cohorts, highlighting the potential of advanced biomarker approaches to improve treatment selection in oncology.
April 20, 2026 — This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising.
April 20, 2026 — Lantern Pharma (NASDAQ: LTRN) announced it has scheduled a mid-May 2026 Type C meeting with the U. S.
April 20, 2026 — This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that Michael Cola has stepped down as Chief Executive Officer effective immediately at the request of the Board, with Co-founder and Executive Chairman Eric So appointed as Interim CEO while a search for a permanent successor is underway.
April 20, 2026 — NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s strategy as it advances its NRX-100 drug candidate and seeks regulatory support to address severe depression, PTSD and suicidality.
April 20, 2026 — This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.
April 20, 2026 — Gold ended the week trading within a limited range as traders and investors remained uncertain about the near-term outlook of prices. Investors remain cautious as there is uncertainty about how talks between the United States and Iran will play out while the clock is ticking down on the 14-day ceasefire that paved the way for these talks.